Clicky

Vivesto AB(VIVE)

Description: Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.


Keywords: Organic Compounds Prostate Cancer Lymphoma Ovarian Cancer Ketones Treatment Of Prostate Cancer Docetaxel Paclitaxel Treatment Of Ovarian Cancer Doxorubicin Encapsulation Technology Carbamates Carbonyl Compounds Taxanes

Home Page: www.vivesto.com

Gustav III:s Boulevard 46
Solna, 169 73
Sweden
Phone: 46 18 50 54 40


Officers

Name Title
Dr. Christer Nordstedt M.D., Ph.D. Acting Chief Exec. Officer
Mr. Robert Maiorana Head of Accounting & Acting CFO
Mr. Kai Wilkinson Chief Technical Officer
Dr. Reinhard Koenig Chief Scientific Officer
Mr. Urban Ekelund IR Mang.
Mr. John T. Cosby Head of Regulatory Affairs
Mr. Dzianis Babrou Head of Product Devel.
Mr. Henrik Rönnberg Chief Medical Officer of Animal Health
Maria Nilsson Hagberg Head of Regulatory Affairs
Ms. Johanna Rostin Head of Regulatory Affairs

Exchange: ST

Country: SE

Currency: Swedish krone (kr)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4143
Price-to-Sales TTM: 26.1882
IPO Date:
Fiscal Year End: December
Full Time Employees: 17
Back to stocks